今年三季度末，单周59家公司拟香港上市公司递表，当中包括24家A股上市公司、2家新三板挂牌公司，还有5家18C特专科技公司。仅9月29日及30日两天， 就有长春高新、贝达药业、百利天恒、晶合集成、极米科技、聚芯微电子等29家公司递表港交所，其中有不少是A+H双重上市。 新增上市则热度爆棚，奥美森北交所挂牌首日大涨349.8%，金叶国际集团以11464.7倍超购成港股"超购王"，挚达科技、长风药业港股上市首日涨幅亦分别 达192.14%、225.42%，新能源、医药赛道备受追捧，资本市场活力持续释放。 一、近期过会 1、广和通拟于港交所主板上市 10月5日，深圳市广和通无线股份有限公司上市聆讯获通过，公司将登陆港交所主板上市，独家保荐人为中信证券。财务数据显示，2022年、2023年、2024 年及2025年前四个月，公司持续经营业务收入分别为52.03亿元、56.52亿元、69.71亿元和24.81亿元，同期持续经营净利润为3.52亿元、3.77亿元、4.23亿元 和1.60亿元。 根据弗若斯特沙利文：公司是全球第二大无线通信模块提供商，公司的全球市场份额为15.4%(以2024年公司来自持续经营业务的收入计 ...

Core Viewpoint - Anuo Youda has submitted its listing application to the Hong Kong Stock Exchange, marking its journey towards going public, backed by influential figure Xia Zuoquan, co-founder of BYD and angel investor in UBTECH [1] Company Overview - Anuo Youda, founded in 2012 by Xia Zuoquan, specializes in IVD medical devices and multi-omics life science research services, becoming a pioneer in NGS-based prenatal testing IVD products [1][3] - The company has developed a comprehensive IVD product portfolio, including approved testing kits, sequencers, and compatible bioinformatics analysis software [3] Market Position - According to data from Zhaoshang Consulting, Anuo Youda ranks third in the Chinese NIPT market by sample testing volume, with a market share of 12.1% [2][3] - The company has significantly increased its sales of IVD products to 86 certified hospitals across 26 provinces, reflecting a growing demand for its offerings [3] Financial Performance - Anuo Youda's revenue projections for 2022 to 2024 are 435 million, 475 million, and 518 million yuan, indicating an upward trend in market demand [3] - Despite rapid business growth, the company is currently operating at a loss, with projected losses of 66.81 million, 240 million, and 126 million yuan for the same period [4] Shareholder Structure - The company boasts a strong shareholder structure, including notable investors such as China Life, Northern Light Venture Capital, Guotai Junan, Ping An Group, and Sequoia Capital, providing financial support and strategic guidance [4] - Xia Zuoquan controls 54.25% of the voting rights through direct and indirect holdings, although daily management is led by CEO Li Zhimin, who has over 30 years of experience in the pharmaceutical and medical industry [4][5] Leadership - Xia Zuoquan is recognized for his visionary leadership and business acumen, which are key to Anuo Youda's success, alongside CEO Li Zhimin's extensive industry insights [5]

最新数据显示，夏佐全目前个人仍位列比亚迪前十大股东之列，持股比例为2.84%，持股数达8263万股，总市值超过300亿元。 | ▶十大股东 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 实际控制人:王传福(直接持股比例:17.65%) | | | | | | | | | I | 2024-12-31 2024-09-30 | 2024-06-30 | 2024-04-12 | 2024-03-31 | 2024-03-05 | 2023-12-31 | 2023-09-30 | 2023-06-3 >> | | 名次 | 股东名称 | | | 股份类型 | 持股数(股) | 占总股本持 股比例 | 增减(股) | 变动比例 | | 1 | HKSCC NOWINEES LINED | | | 流通用股 | 1,097, 459, 799 | 37.72% | 6,100 | 0.00% | | 2 | 干传福 | | | 流通A股,限售流通A股 | 513, 623, 850 | 17. 65% | ...